Comparative Pharmacology
Head-to-head clinical analysis: PARNATE versus TRANYLCYPROMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARNATE versus TRANYLCYPROMINE SULFATE.
PARNATE vs TRANYLCYPROMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible non-selective monoamine oxidase inhibitor (MAOI-A and MAOI-B); increases synaptic concentrations of serotonin, norepinephrine, and dopamine by inhibiting their oxidative deamination.
Irreversible inhibitor of monoamine oxidase (MAO-A and MAO-B), thereby increasing synaptic concentrations of monoamines (e.g., serotonin, norepinephrine, dopamine).
10 mg orally twice daily; increase by 10 mg/day at 1-week intervals up to 60 mg/day; usual therapeutic range 30-60 mg/day in divided doses.
Adults: 10 mg orally twice daily, increasing if necessary after 2 weeks to 30 mg/day in divided doses; maximum 60 mg/day.
None Documented
None Documented
Terminal half-life approximately 2.5 hours; clinically, MAO inhibition persists for 2-3 weeks post discontinuation due to irreversible enzyme binding.
The terminal elimination half-life is approximately 2 hours (range 1.5–3 hours). However, MAO inhibition persists for 7–14 days after discontinuation due to irreversible enzyme binding.
Renal (90% as metabolites, <1% unchanged); fecal (minor).
Renal excretion of metabolites (primarily as conjugates) accounts for approximately 90% of elimination, with less than 1% excreted unchanged in urine. Fecal excretion is minimal.
Category C
Category C
MAOI Antidepressant
MAOI Antidepressant